Published: 23 September 2016
Revised: 8 October 2018
Medical Devices
Surgical Mesh Implants - Implementation of Government Response to Report of the Health Committee on Petition 2011/102
The Health Committee has considered a petition submitted by Carmel Berry and Charlotte Korte requesting an inquiry into the use of surgical mesh in New Zealand. The petition raised several issues around the quality of surgical mesh, the standards of care for patients and the need for a surgical mesh registry.
On 1 June 2016 the Health Committee’s report was presented to the House. This included seven recommendations in three areas: the investigation of options for a surgical registry, improvement in medical practice and the role of the regulator in pre-market medical device approval. A link to the full report follows. https://www.parliament.nz/en/pb/sc/reports/document/51DBSCH_SCR69220_1/petition-20110102-of-carmel-berry-and-charlotte-korte
The Government carefully considered the Committee’s report and supported all of the Committee’s recommendations. The Government Response was tabled on 24 August 2016. A link to the Government Response follows. https://www.parliament.nz/en/pb/papers-presented/current-papers/document/51DBHOH_PAP69804_1/government-response-to-report-of-the-health-committee-on
The following table specifies each of the seven recommendations made by the Health Committee, identifying the actions to ensure the recommendations are implemented and providing a timeline for the implementation of each action.
Health Committee Recommendations and Timeline for Implementation re Surgical Mesh
Recommendation | Actions | Timeline |
---|---|---|
Recommendation 1: That the Government work with relevant medical colleges to investigate options for establishing and maintaining a centralised surgical mesh registry. |
|
To be addressed as part of the development of the new comprehensive regulatory regime to regulate therapeutic products in New Zealand. |
|
Done: Information on the decisions made by Cabinet can be found at the following link https://www.health.govt.nz/our-work/regulation-health-and-disability-system/therapeutic-products-regulatory-regime |
|
|
To be addressed as part of the development of the new comprehensive regulatory regime to regulate therapeutic products in New Zealand. A cost benefit analysis was commissioned on 13 April 2018, and the final report has been provided for review. The cost benefit analysis was published on the Ministry of Health website on 24 September 2018 https://www.health.govt.nz/publication/surgical-mesh-registry-cost-benefit-analysis |
|
Recommendation 2: That a registry be informed by the International Urogynaecological Association classification for recording mesh surgery complications. |
|
See above |
Recommendation 3: That the Government suggests that the Colleges take note of the petitioners’ and others’ experiences and review best practice around informed consent for mesh procedures. |
|
Discussed at the Council of Medical Colleges Board Meeting on
8 December 2016 Ministry of Health established the Mesh Roundtable comprising representatives from the Royal Australasian College of Surgeons (RACS), the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), the Urological Society of Australia and New Zealand (USANZ), the Royal New Zealand College of General Practitioners (RNZCGP), the Accident Compensation Corporation (ACC), the Office of the Health and Disability Commissioner (HDC), the patient advocacy group Mesh Down Under, and the Ministry of Health. Meetings have been held on 20 October 2017, 4 May 2018 and 2 August 2018. Further information on the Mesh Roundtable is published on the Ministry of Health website https://www.health.govt.nz/our-work/hospitals-and-specialist-care/surgical-mesh |
Recommendation 4: That the Government encourages health providers to ensure that coding for mesh surgery is consistent. This should include a system to allow patients with mesh complications to be identified and monitored. |
|
Mesh reporting included in Clinical Coding teleconference with
DHB’s 20 September 2016. |
Recommendation 5: That the Government encourages utilisation of the adverse events reporting system as applicable to medical devices. |
|
|
|
New consumer adverse event reporting form developed in early November 2016. |
|
|
Targetted consumer testing closed 2 December 2016. |
|
|
New form developed and published December 2016. |
|
|
New form developed and published May 2017 |
|
|
Guidance for consumer adverse event form and healthcare professional report form developed and published in December 2016 with new forms. |
|
|
Work ongoing. Progress to date reviewed in meeting on 6 December
2016. Information on all treatment injury claims received by ACC has now been supplied to Medsafe and is included in the updated Medsafe Adverse Event Report |
|
|
Information on the Medsafe website has been updated and new forms published. Links to the information and forms can be located from a number of pages on the website. |
|
Recommendation 6: That the Government endorses the provision of ongoing education for surgeons on the use of surgical mesh and mesh removal surgery. |
|
Discussed at the Council of Medical Colleges Board Meeting on
8 December 2016 On 11 May 2018 the Director-General wrote to all Chief Executive Officers of District Health Boards and private surgical hospitals to remind them that surgical mesh remains an important clinical issue, to update them on recent developments and to describe actions to be taken in response to the information provided in the letter. A copy of this letter is published on the Medsafe website. At 4 May 2018 meeting of Mesh Roundtable group, it was agreed that work on a patient care pathway was a high priority and that further discussion on credentialing of clinicians is to be had. Further information on the Mesh Roundtable is published on the Ministry of Health website https://www.health.govt.nz/our-work/hospitals-and-specialist-care/surgical-mesh |
Recommendation 7: That the Government considers expanding Medsafe’s role over time to assess the quality and safety of a medical device before it can be used in New Zealand. |
The Government is working on a new and comprehensive regulatory regime to regulate therapeutic products in New Zealand, which will replace the Medicines Act 1981. This regime will modernise the regulatory framework for all therapeutic products, including medical devices, and will be flexible enough to ensure effective control over evolving technology. As part of this there will be a pre-market assessment of medical devices requirement and as such a need to increase capacity in medical devices. |
To be addressed as part of the development of the new comprehensive
regulatory regime to regulate therapeutic products in New Zealand.
|